PDCD1 and non-small cell lung carcinoma: Notably, considering that combination therapy augmented the efficacy of anti-PD-1 monotherapy in lung tumor regression associated with decreased blood toxicity, our findings uncover this regimen as a highly effective and advantageous treatment modality for NSCLC.